Drugs / VCL-CB01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00285259 | Jan 2006 → Nov 2009 | Hodgkins lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia +1 | Astellas Pharma Inc | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VCL-CB01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00285259 ↗ |
| Modality | Vaccine | “CMV vaccine” NCT00285259 ↗ |
| Route | Intramuscular | “5 mg/mL, Intramuscular (IM.) 3 vaccinations for donors; 1 vaccination pretransplant, up to 3 vaccinations after transplant for recipients” NCT00285259 ↗ |